Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 75

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 75
---
Also at the August 2, 2025, meeting, Dr. Yeu
reminded the Board that she had previously served as an outside consultant to Alcon, as she had for other companies in the eye care and medical device industry and as discussed with STAAR at the time she joined the Board, and that she had received
fees from Alcon (which, in the last 7 years, had not exceeded $90,000 per year). She also noted that she had terminated her consulting arrangement with Alcon in October 2024 in conjunction with her appointment as the Chief Medical Officer of Tarsus
Pharmaceuticals, Inc., and that she had accordingly not received any consulting fees from Alcon since November 2024. Following this disclosure, Dr. Yeu recused herself from the meeting and, in her absence, the Board determined that Dr. Yeu
did not have an interest in Alcon or the potential transaction with Alcon that would impair her ability to exercise her independent business judgment in evaluating the potential transaction with Alcon.

In addition, the Board reviewed certain disclosures that had been provided by Citi regarding Citi’s relationships with STAAR and Alcon,
and determined that none of the matters set forth in the disclosure would limit Citi’s ability to fulfill its responsibilities as financial advisor to STAAR in connection with the transaction. At the conclusion of the August 2, 2025
meeting, the Board reviewed the proposed terms of Citi’s engagement letter and, following discussion, authorized STAAR management to engage Citi as STAAR’s financial advisor in connection with the proposed transaction. Citi reviewed its
disclosure regarding its relationships with STAAR and Alcon with the Board prior to the execution of the Merger Agreement on August 4, 2025.

On August 3, 2025, Mr. Farrell had discussions with a representative of Broadwood. In these discussions, the representative of
Broadwood indicated that Broadwood would likely not support such an acquisition and that Broadwood would consider taking actions to prevent the consummation of an acquisition.

On August 3, 2025, in response to outreach from a member of the Board, Party A and Party B emailed Mr. Farrell to express interest
in exploring potential opportunities with STAAR. Neither outreach included any proposal on valuation, timing, diligence requirements, financing capability, transaction or other transaction terms.

Also on August 3, 2025, the Board met with members of STAAR’s management with